Meta-Analysis of Randomized, Double Blind, Controlled Studies Confirms the Efficacy and Safety of Esberitox in the Treatment of the Common Cold

Authors

  • Belal Naser Schaper & Brümmer GmbH & Co. KG, Salzgitter, Germany
  • Jörg Schnitker Dr. Jörg Schnitker (IAS), Bielefeld, Germany
  • Christian Hentschel Internal Medicine, Allergology and Natural Therapy, Düsseldorf, Germany
  • Jennifer-Christin Kuchernig Schaper & Brümmer GmbH & Co. KG, Salzgitter, Germany
  • Annette Holtdirk Dr. Jörg Schnitker (IAS), Bielefeld, Germany
  • Gerd Schöneberg Dr. Jörg Schnitker (IAS), Bielefeld, Germany
  • Petra Nicken Schaper & Brümmer GmbH & Co. KG, Salzgitter, Germany
  • Klaus-Ulrich Nolte Schaper & Brümmer GmbH & Co. KG, Salzgitter, Germany
  • Hans-Heinrich Henneicke-von Zepelin Schaper & Brümmer GmbH & Co. KG, Salzgitter, Germany

DOI:

https://doi.org/10.12970/2308-8044.2021.09.04

Keywords:

Metaanalysis, Common colds, Esberitox, Baptisia, Echinacea, Thuja

Abstract

Herbal medicines like Esberitox (TOX, wild indigo root stock, echinacea root, thuja tips and leaves) are used to treat common colds. Several randomized, controlled trials (RCT) document the efficacy and safety of TOX in this indication. So far its efficacy and safety has not been evaluated meta-analytically.

We included individual patient data from all 825 patients from 3 RCTs. 693 patients had been treated with TOX, 132 with placebo (PLA) (7-9 days). All symptom scores were adjusted to baseline and meta-analyzed regarding area under the curve (AUC), time to response (≥50% decrease of symptom score), response rate and duration of the cold.

The AUCs of the rhinitis score were 19.05 with TOX superior to 20.57 with PLA (p=0.020), bronchitis score 14.92 versus 16.16 (p=0.039) and well-being 208.4 versus 216.4 (p=0.008). Response rates were higher in TOX than PLA in all scores. The times to response showed an acceleration of the healing process of rhinitis (1.5 days, p=0.049), bronchitis (2 days) and pain (2 days, p=0.008). The duration of the cold was shortened by TOX by up to 2.3 days. The ADR-rate did not differ significantly (2.7% vs. 1.5%, p=0.41). Tolerability was good to very good in 98.4% (TOX) and 99.2% (PLA) (p=0.34). In conclusion, this meta-analysis confirmed the efficacy and tolerability of Esberitox at a higher level of evidence. It accelerates the improvement of cold symptoms by up to 2 days and shortens the duration of colds by up to 2.3 days.

References

Arroll B. Common cold. BMJ Clinical Evidence 2011; 6(1510): 1-10.

May L, Mullins P, Pines J. Demographic and treatment patterns for infections in ambulatory settings in the United States, 2006-2010. Acad Emerg Med 2014; 21(1): 17-24. https://doi.org/10.1111/acem.12287

Gonzales R. Principles of appropriate antibiotic use for treatment of acute respiratory tract infections in adults: Background, specific aims, and methods. Annals of Internal Medicine 2001; 134(6): 479. https://doi.org/10.7326/0003-4819-134-6-200103200-00013

Fendrick A. The Economic Burden of Non–Influenza-Related Viral Respiratory Tract Infection in the United States. Arch Intern Med 2003; 136: 487-494. https://doi.org/10.1001/archinte.163.4.487

Royston L, Tapparel C. Rhinoviruses and Respiratory Enteroviruses: Not as Simple as ABC. Viruses 2016; 8(1). https://doi.org/10.3390/v8010016

Cotton MF, et al. Management of upper respiratory tract infections in children. South African Family Practice 2008; 50(2): 6-12. https://doi.org/10.1080/20786204.2008.10873685

Harris AM, Hicks LA, Qaseem A. Appropriate Antibiotic Use for Acute Respiratory Tract Infection in Adults: Advice for High-Value Care From the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med 2016; 164(6): 425-34. https://doi.org/10.7326/M15-1840

HMPC (Committee on Herbal Medicinal Products) at the European Medicines Agency (EMA), Assessment report on Echinacea purpurea (L.) Moench, radix 2016.

HMPC (Committee on Herbal Medicinal Products) at the European Medicines Agency (EMA), Assessment report on Echinacea pallida (Nutt.) Nutt., radix 2018.

Weiss JR, Tessema B, Brown SM. Complementary and integrative treatments: upper respiratory infection. Otolaryngol Clin North Am 2013; 46(3): 335-44. https://doi.org/10.1016/j.otc.2012.12.007

Grief SN. Upper respiratory infections. Prim Care 2013; 40(3): 757-70. https://doi.org/10.1016/j.pop.2013.06.004

Bodinet C, et al. Effect of an orally applied herbal immunomodulator on cytokine induction and antibody response in normal and immunosuppressed mice. Phytomedicine 2002; 9(7): 606-13. https://doi.org/10.1078/094471102321616418

Bodinet C. et al. Influence of peroral application of a herbal immunomodulator on the antibody production of Peyer's patches cells. Arzneimittelforschung 2004; 54(2): 114-8. https://doi.org/10.1055/s-0031-1296945

Bostelmann HC, et al. Immunmodulation durch pflanzliche Wirkstoffe - Doppelblindstudie an einer medizinischen Universitätsklinik am Adjuvansmodell zur Hepatitis-B-Impfung. [Immunomodulation by herbal agents. A double-blind study in a medical university hospital involving a hepatitis B vaccine adjuvant model]. Fortschr Med Orig 2002; 120(4): 119-23.

Reitz H-D, HH. Immuno-modulators with phytotherapeutic agents - part 2: a scientific study with Esberitox® N [Immunmodulatoren mit pflanzlichen Wirkstoffen- 2. Teil: eine wissenschaftliche Studie am Beispiel Esberitox® N]. Notabene Medici 1990; 20(7-8): 362-366.

Zimmer M. Gezielte konservative Therapie der akuten Sinusitis in der HNO-Praxis [Specific conservative treatment of acute sinusitis in the ENT practice]. Therapiewoche 1985; 35(36): 4024-4028.

Naser B, et al. A randomized, double-blind, placebo-controlled, clinical dose-response trial of an extract of Baptisia, Echinacea and Thuja for the treatment of patients with common cold. Phytomedicine 2005; 12(10): 715-22. https://doi.org/10.1016/j.phymed.2005.03.002

Henneicke-von Zepelin H-H, et al. Efficacy and safety of a fixed combination phytomedicine in the treatment of the common cold (acute viral respiratory tract infection): results of a randomised, double blind, placebo controlled, multicentre study. Curr Med Res Opin 1999’ 15(3): 214-27. https://doi.org/10.1185/03007999909114094

CPMP E, Points to Consider on Application with 1. Meta-Analyses; 2. One Pivotal Study, E. CPMP, Editor. 2001; London. p. 7.

Welzel D, et al. Farbskalen zur Messung von Befindlichkeit und Lebensqualität, in Befunderhebung in der Psychiatrie: Lebensqualität, Negativsymptomatik und andere aktuelle Entwicklungen, H.-J. Möller, R.R. Engel, and P. Hoff, Editors. 1996, Springer Vienna. p. 133-152. https://doi.org/10.1007/978-3-7091-6574-4_11

DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials 2015; 45(Pt A): 139-45. https://doi.org/10.1016/j.cct.2015.09.002

O'Brien PC. Procedures for Comparing Samples with Multiple Endpoints. Biometrics 1984; 40(4): 1079. https://doi.org/10.2307/2531158

Lehmacher W, Wassmer G, Reitmeir P. Procedures for Two-Sample Comparisons with Multiple Endpoints Controlling the Experimentwise Error Rate. Biometrics 1991; 47: 511-521. https://doi.org/10.2307/2532142

Kenealy T, Arroll B. Antibiotics for the common cold and acute purulent rhinitis. Cochrane Database Syst Rev 2013; (6): Cd000247. https://doi.org/10.1002/14651858.CD000247.pub3

Burkhardt O, et al. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. Eur Respir J 2010; 36(3): 601-607. https://doi.org/10.1183/09031936.00163309

de Sécurité AF, de Santé SDP. National Guidelines - Systematic antibiotic treatment in upper and lower respiratory tract infections: official French guidlines. Clinical Microbiology and Infection 2003; 9(12): 1162-1178. https://doi.org/10.1111/j.1469-0691.2003.00798.x

(ISCI), I.f.C.S.I., Guideline summary NGC-6369: Diagnosis and treatment of respiratory illness in children and adults. ICSI: Blomington (MN) 2008; p. 71.

Thompson M, et al. Duration of symptoms of respiratory tract infections in children: systematic review. BMJ 2013; 347: f7027. https://doi.org/10.1136/bmj.f7027

Hemila H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev 2013; (1): Cd000980. https://doi.org/10.1002/14651858.CD000980.pub4

HMPC (Committee on Herbal Medicinal Products) at the European Medicines Agency (EMA), European Union herbal monograph on Echinacea pallida (Nutt.) Nutt., radix 2018.

HMPC (Committee on Herbal Medicinal Products) at the European Medicines Agency (EMA), European Union herbal monograph on Echinacea purpurea (L.) Moench, radix 2017.

David S, Cunningham R. Echinacea for the prevention and treatment of upper respiratory tract infections: A systematic review and meta-analysis. Complement Ther Med 2019; 44: 18-26. https://doi.org/10.1016/j.ctim.2019.03.011

Freitag U. Shortened duration of disease due to a non-specific immunostimulant in pertussis [Reduzierte Krankheitsdauer bei Pertussis durch unspezifisches Immunstimulans]. Der Kinderarzt 1984; 15: 1068-1071.

Hauke W, et al. Esberitox® N as supportive therapy when providing standard antibiotic treatment in subjects with a severe bacterial infection (acute exacerbation of chronic bronchitis). Chemotherapy 2002; 48(5): 259-266. https://doi.org/10.1159/000066763

Stolze H, Forth H. A treatment with antibiotics can be optimized by additional immunestimulation [Eine Antibiotikabehandlung kann durch zusätzliche Immunstimulierung optimiert werden]. Der Kassenarzt 1983; 23: 43-8.

von Blumröder WO. Angina lacunaris - Eine Untersuchung zum Thema "Steigerung der körpereigenen Abwehr". Z allg Med 1985; 61(8): 271-273.

Downloads

Published

2021-09-09

Issue

Section

Articles